Tetrous

Media Contact:

Bradley Patt, PhD
Tetrous, Inc.
818-645-4081
bpatt@tetrous.com

Product Information:

John Bojanowski
Tetrous, Inc.
978-809-0374
jbojanowski@tetrous.com

TETROUS®, INC. SIGNS NEW DISTRIBUTION AGREEMENT IN NEW ZEALAND TO EXPAND PRESENCE IN THE ASIA-PACIFIC MARKET AND ADDS DR. CRAIG BALL TO IT’S SURGEON ADVISORY BOARD

Los Angeles, CA, March 19, 2025 – Tetrous, Inc., a Sherman Oaks start up focused on bone-to-tendon healing following orthopedic surgery, is pleased to announce the signing of a new distribution agreement with Alpha Medical, a well-established distributor in New Zealand. Additionally, Dr. Craig Ball, a pre-eminent shoulder surgeon in New Zealand has agreed to join Tetrous’ Clinical Advisory Board. These strategic partnerships will expand existing distribution of Tetrous products already fully commercialized in the US, and in Australia by Australian Biotechnologies, to now include distribution in New Zealand with Alpha Medical.

As part of the agreement, Alpha Medical will have exclusive distribution rights in New Zealand for the Tetrous EnFix® demineralized bone fiber implants intended for enthesis repair in shoulder, elbow, hip, knee and ankle procedures. Alpha Medical has an extensive range of high-quality, innovative products and an experienced team committed to providing superior solutions that support successful surgical outcomes and patient recovery.

“We are thrilled to partner with Alpha Medical, a respected medical distribution leader in New Zealand”, said John Bojanowski, Chief Commercial Officer at Tetrous. “Their experience with biologic products and their dedication to improving patient outcomes makes them the ideal partner to promote and distribute Tetrous’ products. Having Dr. Craig Ball join our Clinical Advisory Board and begin clinical use of EnFix imminently at Southern Cross Healthcare – Brightside Hospital, Auckland, NZ will ensure we get off to a great start.”

“I am eager to trial the Tetrous EnFix product. Biologic augmentation in the rotator cuff has not been an easy task to accomplish and yet could be the key to proper healing. The EnFix implant is a minimally disruptive way for me to add this crucial element to help my patients recover faster”, said Dr. Ball.

“We are excited to represent Tetrous in New Zealand and add their innovative EnFix implants to our portfolio”, said Brandon Hiini, CEO of Alpha Medical. “The high quality and uniqueness of Tetrous’ solutions align perfectly with our commitment to New Zealand’s healthcare professionals and patients”.

The EnFix® family of allograft products are designed to enhance healing at the enthesis, where failure often occurs. The implants are 100% demineralized bone fiber (DBF), providing osteoinductivity and osteoconductivity, resulting in optimal biologic performance with minimal disruption to current surgical techniques.

This new collaboration marks a key milestone in Tetrous’ ongoing global expansion efforts. The company remains committed to driving innovation in the sports medicine market and delivering advanced, reliable solutions that enhance patient care. It’s All About the Enthesis™.

###

About Tetrous, Inc.

Founded in 2019, Tetrous, Inc. utilizes next generation advanced technologies for enthesis repair in sports medicine applications. The first offerings in the EnFix family of products are EnFix RC and EnFix TAC for rotator cuff repair. Tetrous was conceived from technology developed for spine surgery. The Company is employing and expanding the technology for novel applications in sports medicine. Its core technology has been used in over 150,000 implants in spine applications. Tetrous enjoys significant IP protection for its EnFix family of products with multiple issued patents and, additionally, has an exclusive license to the demineralized bone fiber technology used in its products for sports medicine applications from TheraCell, an ISTO Biologics Company.

About Alpha Medical

The name Alpha Medical originates from the first letter of the Greek alphabet. This name drives an inspiration to prioritise patients and clinicians while supplying medical technology innovation across New Zealand. Alpha Medical is an independent supplier of high-quality medical devices that are curated and sourced from around the world. With a focus upon orthopaedics and sports medicine surgery since the business was founded in 2023, Alpha’s products are supported and supplied by a team of experienced industry experts. www.alphamedical.nz

EnFix®, EnFix RC™, EnFix TAC™, and It’s All About the Enthesis™ are trademarks of Tetrous, Inc.
FormLok™ is a trademark of TheraCell, Inc., an Isto Biologics company.

For  more information visit www.tetrous.com and follow us on LinkedIn (www.linkedin.com/company/tetrous).

Tetrous

© Tetrous, Inc. All rights reserved.

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous.

Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions.

Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women.

Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum.

Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous. Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions. Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women. Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum. Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.